[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2009012990A - Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica. - Google Patents

Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica.

Info

Publication number
MX2009012990A
MX2009012990A MX2009012990A MX2009012990A MX2009012990A MX 2009012990 A MX2009012990 A MX 2009012990A MX 2009012990 A MX2009012990 A MX 2009012990A MX 2009012990 A MX2009012990 A MX 2009012990A MX 2009012990 A MX2009012990 A MX 2009012990A
Authority
MX
Mexico
Prior art keywords
muscle relaxant
providing
stable
botulinum toxin
basis
Prior art date
Application number
MX2009012990A
Other languages
English (en)
Inventor
Matthias Marx
Karl-Heinz Eisele
Harold V Taylor
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07010912A external-priority patent/EP1997509A1/en
Priority claimed from EP07020025A external-priority patent/EP2048156A1/en
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2009012990A publication Critical patent/MX2009012990A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invenci?n proporciona un proceso para proporcionar un relajante muscular, donde el relajante muscular es una soluci?n reconstituida que comprende un componente neurot?xico de toxina botul?nica libre de prote?nas complejantes, que exhibe al menos una de las siguientes caracter?sticas, de manera m?s preferible todas las caracter?sticas a) a d): a) Estable a temperaturas de almacenamiento superiores a 20?C; b) estable en presencia de preservativos y/o analg?sico; c) resistente contra ciclos de "congelamiento y descongelamiento"; d) estable si se almacena en recipientes de diferente material.
MX2009012990A 2007-06-01 2008-05-28 Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica. MX2009012990A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93262407P 2007-06-01 2007-06-01
EP07010912A EP1997509A1 (en) 2007-06-01 2007-06-01 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
US99885807P 2007-10-12 2007-10-12
EP07020025A EP2048156A1 (en) 2007-10-12 2007-10-12 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
PCT/EP2008/004254 WO2008145359A1 (en) 2007-06-01 2008-05-28 Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin

Publications (1)

Publication Number Publication Date
MX2009012990A true MX2009012990A (es) 2010-04-01

Family

ID=40074591

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009012990A MX2009012990A (es) 2007-06-01 2008-05-28 Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica.
MX2009012570A MX2009012570A (es) 2007-06-01 2008-05-28 Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009012570A MX2009012570A (es) 2007-06-01 2008-05-28 Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida.

Country Status (15)

Country Link
US (2) US20090028906A1 (es)
EP (2) EP2164861A1 (es)
JP (2) JP2010528999A (es)
KR (2) KR20100020971A (es)
CN (2) CN101720331A (es)
AR (2) AR066782A1 (es)
AU (2) AU2008256419A1 (es)
BR (2) BRPI0812322A2 (es)
CA (2) CA2686642A1 (es)
IL (2) IL202129A0 (es)
MX (2) MX2009012990A (es)
RU (1) RU2009149604A (es)
TW (2) TW200914039A (es)
WO (2) WO2008145358A1 (es)
ZA (2) ZA200907875B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
BRPI0923731B1 (pt) 2008-12-31 2024-02-06 Revance Therapeutics, Inc Composições para uso em um método não-terapêutico de administração de toxina botulínica, seus usos e método de preparação
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
KR101806567B1 (ko) * 2009-02-19 2018-01-10 메르츠 파마 게엠베하 운트 코. 카가아 매우 순수한 신경독을 제조하기 위한 수단 및 방법
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
JP5689113B2 (ja) * 2009-04-27 2015-03-25 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー ニューロトキシンポリペプチドの量の測定とその触媒及びタンパク質分解活性の測定のための手段及び方法
KR101804279B1 (ko) 2009-06-25 2017-12-05 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
US20120196349A1 (en) * 2009-10-21 2012-08-02 Revance Therapeutics, Inc. Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
HUE050037T2 (hu) * 2011-03-31 2020-11-30 Medy Tox Inc Liofilizált botulinum toxin készítmény
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
KR101357999B1 (ko) * 2012-03-20 2014-02-03 함종욱 보툴리눔 에이형 독소의 액상제품
MX2017007476A (es) * 2014-12-23 2018-01-25 Merz Pharma Gmbh & Co Kgaa Recipiente precargado con toxina botulinica.
US10406290B2 (en) * 2015-02-03 2019-09-10 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled plastic syringe
EP3070539A1 (fr) * 2015-03-17 2016-09-21 Omega SA Montre-bracelet comprenant un cadran muni d'index lumineux
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
WO2020138674A1 (ko) 2018-12-26 2020-07-02 (주)케어젠 근육 이완용 조성물
MX2020014330A (es) 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
WO2023186016A1 (zh) * 2022-04-01 2023-10-05 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物、制备方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
CA2578250C (en) * 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
CA2612205C (en) 2005-06-17 2012-07-10 Merz Pharma Gmbh & Co. Kgaa Apparatus and process for the fermentative production of biological active compounds
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica

Also Published As

Publication number Publication date
IL202130A0 (en) 2010-06-16
MX2009012570A (es) 2010-03-15
JP2010528999A (ja) 2010-08-26
US20090010965A1 (en) 2009-01-08
AR066782A1 (es) 2009-09-09
EP2170375A1 (en) 2010-04-07
CN101720331A (zh) 2010-06-02
ZA200907875B (en) 2010-11-24
US20090028906A1 (en) 2009-01-29
ZA200907874B (en) 2011-03-30
KR20100020972A (ko) 2010-02-23
WO2008145359A1 (en) 2008-12-04
JP2010529000A (ja) 2010-08-26
CN101687018A (zh) 2010-03-31
AU2008256419A1 (en) 2008-12-04
RU2009149604A (ru) 2011-07-20
AR066783A1 (es) 2009-09-09
WO2008145358A1 (en) 2008-12-04
IL202129A0 (en) 2010-06-16
AU2008256418A1 (en) 2008-12-04
TW200902050A (en) 2009-01-16
KR20100020971A (ko) 2010-02-23
CA2686642A1 (en) 2008-12-04
CA2686637A1 (en) 2008-12-04
BRPI0812322A2 (pt) 2014-11-25
TW200914039A (en) 2009-04-01
BRPI0812245A2 (pt) 2014-10-21
EP2164861A1 (en) 2010-03-24

Similar Documents

Publication Publication Date Title
MX2009012990A (es) Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica.
MY188973A (en) Activin-actrii antagonists and uses for treating anemia
EP1928226A4 (en) TOLERANCE OF PLANTS WITH STRESS
WO2006134190A3 (es) Agentes y métodos basados en el uso del dominio eda de la fibronectina
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2008006422A3 (de) Verwendung von ionischen flüssigkeiten oder lösungen aus metallsalzen in ionischen flüssigkeiten als antistatika für kunststoffe
WO2009109908A8 (en) Methods of treating inflammatory pain
MX358013B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
WO2009126292A3 (en) Biologically active peptidomimetic macrocycles
WO2006124641A3 (en) Anti-mesothelin antibodies useful for immunological assays
WO2008140594A3 (en) Peptide nanoparticles and uses therefor
WO2008063213A3 (en) Uses and compositions for treatment of psoriatic arthritis
WO2008063842A3 (en) Methods of treating neuropathic pain with agonists of ppar-gamma
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
GB2447180A (en) Property rating and ranking system and method
WO2008057409A3 (en) Sanitizing surfaces
WO2007044396A3 (en) Fibronectin polypeptides and methods of use
WO2007120651A3 (en) Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2008049056A3 (en) Treatment of medical condition with a2 domain of von willebrand factor
WO2008127355A3 (en) Chemorepulsion of cells
WO2008084309A3 (en) Drm-protected content sharing
MX2011004483A (es) Leucolectinas y sus usos.
WO2006135493A3 (en) A composition for wound healing and use thereof
TW200716159A (en) Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells

Legal Events

Date Code Title Description
FA Abandonment or withdrawal